The potential and hurdles of targeted alpha therapy - clinical trials and beyond.
about
In Vivo Radionuclide Generators for Diagnostics and TherapySafety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.GD2-targeted immunotherapy and radioimmunotherapyDose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation.Triple targeting of Auger emitters using octreotate conjugated to a DNA-binding ligand and a nuclear localizing signal.In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.Development of a transmission alpha particle dosimetry technique using A549 cells and a Ra-223 source for targeted alpha therapy.A review of solute encapsulating nanoparticles used as delivery systems with emphasis on branched amphipathic peptide capsules.B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models.Imaging and dosimetry for radium-223: the potential for personalized treatment.Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases.Irradiation of Mesenchymal Stromal Cells With Low and High Doses of Alpha Particles Induces Senescence and/or Apoptosis.Targeted α Therapies for the Treatment of Bone Metastases.212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models.212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models.Radium and other alpha emitters in prostate cancer
P2860
Q28818650-7D3B9A43-E083-4D1B-B12A-A00059C1A105Q30490448-17D4123B-9234-410D-AD79-4A6B2E5FDBB3Q33629621-0E5FBF37-59B3-4369-92F2-FB64FDB9A4BCQ34625339-850F82EC-8747-4D55-BB43-6B16461D72BBQ35800092-66446093-2E20-4DE3-A51A-92A8CDB5D199Q35847776-E4DE7FEB-4F92-4889-8C00-EDB80C2761AAQ37686296-564C0F2E-196A-4C30-88EC-12185597562BQ38293084-1A17E802-EE2D-4D3A-B398-28861F887350Q38696649-0101B356-5F67-497F-A30E-D387C4FBD402Q38733823-770AB26A-9EA6-4468-B619-6B4AD53DDF6AQ38754657-BA2250F3-EB16-4497-AE0F-D8DC825965E4Q38768316-C417DB31-AA1B-42A0-8F43-0E67B34F8F21Q39400630-9495400B-2601-48DA-B48B-F825AF16C208Q47152190-D025C113-E656-4694-A4A3-8C353CE0E174Q48045979-19CB5E02-BE3A-4C9D-9219-FA6DEDB17893Q49271846-CCC7A997-F01A-450B-BB4A-161CD31DC293Q50138482-F1D0F748-1BA1-4BBA-8032-0E6F1F1E58DCQ55042518-42503D2C-6E50-425B-90EA-87E20C8498B2Q57112384-93C4842E-1F83-4EC6-891F-6A28EE60D5A5
P2860
The potential and hurdles of targeted alpha therapy - clinical trials and beyond.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The potential and hurdles of targeted alpha therapy - clinical trials and beyond.
@ast
The potential and hurdles of targeted alpha therapy - clinical trials and beyond.
@en
The potential and hurdles of targeted alpha therapy - clinical trials and beyond.
@nl
type
label
The potential and hurdles of targeted alpha therapy - clinical trials and beyond.
@ast
The potential and hurdles of targeted alpha therapy - clinical trials and beyond.
@en
The potential and hurdles of targeted alpha therapy - clinical trials and beyond.
@nl
prefLabel
The potential and hurdles of targeted alpha therapy - clinical trials and beyond.
@ast
The potential and hurdles of targeted alpha therapy - clinical trials and beyond.
@en
The potential and hurdles of targeted alpha therapy - clinical trials and beyond.
@nl
P2093
P2860
P356
P1476
The potential and hurdles of targeted alpha therapy - clinical trials and beyond
@en
P2093
Jean-Pierre Pouget
Jörgen Elgqvist
Sofia Frost
P2860
P356
10.3389/FONC.2013.00324
P577
2014-01-14T00:00:00Z